{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:46:05Z","timestamp":1785735965905,"version":"3.56.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Oncolytic herpes simplex virus type-1 (HSV1)\u2013based therapies engage innate immune responses, including natural killer (NK) cells, which are regarded as antiviral effector cells that eliminate virus-infected tumor targets. In this study, we examined interactions between the HSV1\u2013derived oncolytic virus HSV1716 and primary human NK cells. Co-culture experiments revealed increased activation and degranulation of NK cells in response to HSV1716-infected tumor cells, despite the downregulation of ligands for NK-cell activating receptors on infected targets. Following co-culture with infected tumor cells, but not after incubation with viral inoculum alone, viral gene expression and increased viral copy numbers were detected in NK cells, indicating enhanced viral acquisition and persistence associated with target-cell contact. HSV1716-infected NK cells displayed impaired tumor cell killing ability. Single-cell sequencing analysis revealed downregulation of key NK effector genes alongside alterations in stress-response pathways in HSV1716 infected NK cells. Together, these findings demonstrate that primary human NK cells are infected by HSV1716 and undergo functional and phenotypic changes, leading to a diminished cytotoxic capacity. Given the emerging role of NK cell\u2013based therapies in cancer, these findings may be relevant for the design and timing of oncolytic virus\u2013based strategies in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1895832","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:31:10Z","timestamp":1785735070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic HSV1716 attenuates tumor-killing activity of infected primary NK cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Katharina H.","family":"Susek","sequence":"first","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Holla","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Marsal","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Kashif","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Albert","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Flore","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Gilljam","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Karvouni","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Meinke","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnika K.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Powers","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Allen","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"Alici","sequence":"additional","affiliation":[{"name":"Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.11.001","article-title":"Characterization of human natural killer cells for therapeutic use","volume":"21","author":"Wagner","year":"2019","journal-title":"Cytotherapy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2021.152097","article-title":"Selective downregulation of natural killer activating receptors on NK cells and upregulation of PD-1 expression on T cells in children with severe and\/or recurrent herpes simplex virus infections","volume":"226","author":"Lenart","year":"2021","journal-title":"Immunobiology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17173","article-title":"Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms","volume":"192","author":"Oku","year":"2021","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3013","article-title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors","volume":"18","author":"Alvarez-Breckenridge","year":"2012","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1715295115","article-title":"Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy","volume":"115","author":"Kim","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1128\/jvi.68.1.48-55.1994","article-title":"ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures","volume":"68","author":"Bolovan","year":"1994","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02241.x","article-title":"Herpes simplex virus infection downmodulates NKG2D ligand expression","volume":"69","author":"Schepis","year":"2009","journal-title":"Scand J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.09.077","article-title":"HSV1 microRNA modulation of GPI anchoring and downstream immune evasion","volume":"17","author":"Enk","year":"2016","journal-title":"Cell Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.021931-0","article-title":"Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112","volume":"91","author":"Prod'homme","year":"2010","journal-title":"J Gen Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ni1156","article-title":"Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141","volume":"6","author":"Tomasec","year":"2005","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1409485111","article-title":"Modulation of CD112 by the alphaherpesvirus gD protein suppresses DNAM-1-dependent NK cell-mediated lysis of infected cells","volume":"111","author":"Grauwet","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1003","article-title":"Bortezomib treatment sensitizes oncolytic HSV-1-treated tumors to NK cell immunotherapy","volume":"22","author":"Yoo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.3.1267-1274.2000","article-title":"Nectin2alpha (PRR2alpha or HveB) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D","volume":"74","author":"Lopez","year":"2000","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1086\/512862","article-title":"Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors","volume":"195","author":"Chisholm","year":"2007","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1666","article-title":"Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity","volume":"22","author":"Suryadevara","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007784","article-title":"Functional paralysis of human natural killer cells by alphaherpesviruses","volume":"15","author":"Campbell","year":"2019","journal-title":"PloS Pathog"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006999","article-title":"Varicella zoster virus productively infects human natural killer cells and manipulates phenotype","volume":"14","author":"Campbell","year":"2018","journal-title":"PloS Pathog"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.617578","article-title":"Herpes simplex virus cell entry mechanisms: An update","volume":"10","author":"Madavaraju","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02163-08","article-title":"The virological synapse facilitates herpes simplex virus entry into T cells","volume":"83","author":"Aubert","year":"2009","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.08.020","article-title":"First-in-human intravenous seprehvir in young cancer patients: A phase 1 clinical trial","volume":"27","author":"Streby","year":"2019","journal-title":"Mol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/futurepharmacol2040029","article-title":"Macrophage delivered HSV1716 is active against triple negative breast cancer","volume":"2","author":"Kwan","year":"2022","journal-title":"Future Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2471\/blt.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull World Health Organ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:31:11Z","timestamp":1785735071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1895832"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1895832","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1895832"}}